CORE 4- Small Animal Core

摘要-小动物核心 我们疫苗开发计划的一个关键组成部分是对小鼠候选抗原的效力测试 艰难梭菌感染模型。我们计划的小动物核心将实现这一目标并确定领导 用于开发预防CDI的新型疫苗的抗原。小动物核心将由Dr。 埃里克·斯卡。Skaar实验室在艰难梭菌感染的小鼠模型方面拥有丰富的经验，并已 还开发了一种新的艰难梭菌活疫苗模型，如项目2所述。此外，Skaar 实验室有经验测试小分子和抗体对小鼠的治疗效果 模特们。这一经验将被用来指导创建一个小动物核心来测试铅的功效 由这个项目开发的抗原。小动物核心将受益于翻译公司的专业知识 病理共享资源(TPSR)，包括访问委员会认证的兽医病理学家 在活体模拟人类疾病方面的经验，包括分子病理学、毒理学评估、 以及数字病理学以及兽医解剖病理学和小鼠模型方面的高级培训。这个 小动物核心将接受来自科学核心2的优化候选抗原。这些蛋白质将进行测试 寻找合适的CDI小鼠模型的疗效。候选抗原将单独或组合进行测试。 综合起来，小动物核心的努力将导致确定发育所需的铅抗原 用于预防艰难梭菌引起的感染的新型疫苗。

SUMMARY-SMALL ANIMAL CORE A critical component of our vaccine development program is efficacy testing of candidate antigens in murine models of C. difficile infection. The Small Animal Core of our program will achieve this goal and identify lead antigens for the development of novel vaccines to prevent against CDI. The Small Animal Core will be led by Dr. Eric Skaar. The Skaar laboratory has significant experience in the murine model of C. difficile infection and has also developed a new live C. difficile vaccine model in mice as described in Project 2. In addition, the Skaar laboratory has experience testing the therapeutic efficacy of both small molecules and antibodies in murine models. This experience will be used to guide the creation of a Small Animal Core to test the efficacy of lead antigens developed by this program. The Small Animal Core will benefit from the expertise of the Translational Pathology Shared Resource (TPSR) which includes access to a board-certified veterinary pathologist with experience in in vivo modeling of human disease, including molecular pathology, toxicopathologic assessment, and digital pathology as well as advanced training in veterinary anatomic pathology and murine models. The Small Animal Core will receive optimized candidate antigens from Scientific Core 2. These proteins will be tested for efficacy in appropriate murine models of CDI. Candidate antigens will be tested alone or in combination. Combined, the efforts of the Small Animal Core will result in the identification of lead antigens for the development of novel vaccines that protect against infections caused by C. difficile.